Sherlock Hu

Sherlock Hu is the current Chief Information Officer at GV20 Therapeutics. Prior to this, they were a Research Fellow at Dana-Farber Cancer Institute from October 2016 to April 2019, where they worked in Shirley Liu's Lab as a post-doc. Sherlock was also a Research Associate at Institute of Biophysics, Chinese Academy of Science from September 2015 to September 2016, where they worked on building up the computational environment and analyzing RNA-seq, ChIP-seq, and CLIP-seq data. Prior to that, they were a visiting student at Tsinghua University from July 2014 to September 2014, where they worked on improving RNA secondary structure prediction by adding RNA structural-probing data, matrix analysis on the protein binding sites on RNAs, and the application of deep learning in biology data. Sherlock was also a visiting student at Cornell University from July 2013 to January 2014. Sherlock has also been a teaching assistant at The Chinese University of Hong Kong from December 2010 to July 2014, and a research assistant at City University of Hong Kong from January 2010 to October 2010. Sherlock began their academic career as a visiting student at Fudan University from March 2009 to December 2009.

Sherlock Hu received a Bachelor's degree in Computer Science from Wuhan University. Sherlock then went on to earn a Doctor of Philosophy in Biomathematics, Bioinformatics, and Computational Biology from The Chinese University of Hong Kong.

Some of their coworkers include Ying Gong - Chief Business Officer, Steve Landau - Chief Medical Officer, and Wei Yang - Chief Scientific Officer. Sherlock Hu reports to Shirley Liu, Co-founder & CEO.